The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma

Pellegrino Musto

Research output: Contribution to journalArticle

Abstract

The key role of a blunted production of endogenous erythropoietin (EPO) in determining anemia of patients with multiple myeloma (MM) has been definitively established. Thus, several clinical trials have investigated the effects of recombinant EPO (r-EPO) in anemic MM patients. The results of these studies have demonstrated that r-EPO is a safe and effective drug, which results in an increase in Hb levels in the majority of treated patients. However, several factors, such as serum levels of endogenous EPO, severity of anemia, presence of normal erythroid progenitors, serum levels of some cytokines with inhibitory activity on erythroid function and previous treatments, may significantly affect the possibility of response, thereby suggesting the need for careful selection of MM patients for treatment with r-EPO.

Original languageEnglish
Pages (from-to)283-291
Number of pages9
JournalLeukemia and Lymphoma
Volume29
Issue number3-4
Publication statusPublished - 1998

Keywords

  • Anemia
  • Erythropoietin
  • Multiple myeloma

ASJC Scopus subject areas

  • Cancer Research
  • Hematology
  • Oncology

Fingerprint Dive into the research topics of 'The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma'. Together they form a unique fingerprint.

Cite this